Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years but ≤ 75 years; 2. Histologically or cytologically confirmed advanced lung adenocarcinoma; 3. Chest CT or whole-body PET-CT indicates pleural invasion with pleural effusion, and pleural fluid cytology confirms the presence of cancer cells. After 2 months of treatment with furmonertinib ± thoracentesis drainage, malignant pleural effusion is controlled (no pleural effusion or only ≤ 100 ml of pleural effusion), and a small amount of pericardial effusion may be present; 4. No prior history of thoracic radiotherapy or thoracic surgery; 5. Positive for EGFR-sensitive mutations (19del/L858R); 6. No prior systemic anti-tumor therapy; 7. ECOG performance status 0-1, with a life expectancy of ≥ 12 weeks; 8. At least one measurable lesion (according to RECIST 1.1); 9. Signed informed consent obtained; 10. No more than 3 bone metastases. Exclusion Criteria: 1. Complicated with interstitial pneumonia or infectious fever before treatment; 2. Complicated with autoimmune diseases or long-term oral corticosteroid use; 3. Prior history of thoracic radiotherapy or thoracic surgery; 4. Complicated with severe anemia, grade 3 WBC or PLT suppression; 5. Allergic to third-generation TKIs; 6. Obvious respiratory symptoms, intolerant to radiotherapy; 7. Active hepatitis B or hepatitis C infection, or currently undergoing antiviral treatment; patients with a clear history of HBV infection whose HBV DNA is at an undetectable level after previous active treatment may be enrolled; 8. Poor control or continuous progression of pleural effusion after two consecutive months of TKI treatment; 9. Patients with brain metastases or liver metastases.